Shots:
- Biohavem to receive $500M up front that consists of $150M cash & $350M in the purchase of Biohaven equity at a premium of 25% & are also eligible to receive ~$740M in milestones along with royalties on net sales outside of the US
- Pfizer gets the rights to commercialize zavegepant & rimegepant outside the US while Biohaven will be responsible for the clinical development of rimegepant & will commercialize Nurtec ODT in the US
- Rimegepant is commercialized as Nurtec ODT in the US for the treatment of migraine attacks with/out aura. Additionally, an application for rimegepant’s approval is currently under EMA’s review & other regulatory authorities outside of the US
Click here to read the full press release/ article | Ref: Pfizer | Image: PR Newswire
The post Pfizer Signs a Commercialization Arrangement with Biohaven for Rimegepant to Treat Migraine first appeared on PharmaShots.
